Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterLetter

Hypocomplementemia Associated with Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still’s Disease: 3 Cases

MARK GORELIK, KATHRYN S. TOROK, DANIEL A. KIETZ and RAPHAEL HIRSCH
The Journal of Rheumatology February 2011, 38 (2) 396-397; DOI: https://doi.org/10.3899/jrheum.100833
MARK GORELIK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mark.gorelik@chp.edu
KATHRYN S. TOROK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DANIEL A. KIETZ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RAPHAEL HIRSCH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

Macrophage activation syndrome (MAS) is a life-threatening complication seen in association with childhood inflammatory diseases, most commonly in systemic juvenile idiopathic arthritis (sJIA)1,2,3. MAS has also been described in the setting of adult-onset Still’s disease (AOSD), systemic lupus erythematosus, drug reactions, and viral infections4,5.

Decrease in C3 has been documented in patients with lupus and MAS4; however, to our knowledge, hypocomplementemia has not been previously described as associated with MAS in sJIA or AOSD. We describe 2 patients with sJIA, and a third with AOSD, who developed MAS with hypocomplementemia during the acute phase of illness.

Patient 1, a 9-year-old boy, presented with high quotidian fever, evanescent rash, and arthritis. He had leukocytosis (24 × 109/l) with elevated markers of inflammation: erythrocyte sedimentation rate (ESR) 52 mm/h and C-reactive protein (CRP) 17.3 mg/dl. Liver enzymes and renal function were normal. Ferritin was 5623 ng/ml. Serologic tests for Epstein-Barr virus, parvovirus, cytomegalovirus, Lyme disease, mycoplasma, and group A streptococcus were negative. Complement levels, obtained by the primary intensive care team, showed slightly increased C3 (166 mg/dl) and normal C4 (32 mg/dl). He was discharged with a diagnosis of new-onset sJIA and prescribed indomethacin. Several days later, he returned to clinic with worsening symptoms and petechial rash. Laboratory results are shown in Table 1. Ferritin was markedly elevated. C3 and C4 were profoundly decreased. Aspartate aminotransferase (AST) was mildly elevated and platelets declined over several days from 522 × 109/l to 167 × 109/l. Antinuclear antibodies (ANA), antineutrophil cytoplasmic antibodies (ANCA), anti-Smith, anti-RNP, anti-Ro, and anti-La autoantibodies were negative. He was diagnosed with MAS secondary to sJIA and treated with pulses of methylprednisolone (30 mg/kg/dose) and intravenous immunoglobulin (IVIG; 2 g/kg); he had improvement of symptoms and decrease of ferritin levels to 1533 ng/ml. Complement levels and ferritin measured 2 weeks after steroid pulse had normalized. He has been managed subsequently with anakinra. Since starting anakinra, he has been stable, with occasional flares of mild rash and arthritis due to periodic noncompliance.

View this table:
  • View inline
  • View popup
Table 1.

Laboratory characteristics of patients with macrophage activation system in a setting of sJIA/AOSD during acute and recovery phase of illness. Normal ranges in parentheses.

Patient 2, an 11-year-old girl, presented with high fever, left ankle arthritis, and abdominal pain. She was transferred to our institution from an outside hospital with a fine erythematous, blanching rash and respiratory distress. She arrived in shock with hypotension requiring intubation. She continued to have high fevers (highest 41.3°C) and rash. Initial and subsequent laboratory results are shown in Table 1. They were significant for leukocytosis, elevated ferritin, and elevated markers of inflammation. C3 and C4 concentrations obtained due to unclear clinical setting were low. A bone marrow biopsy showed hemophagocytosis. Extensive evaluation for infectious agents was negative, with the exception of positive serology for adenovirus at the lowest detectable titer. ANA and specific lupus autoantibodies were negative. She was diagnosed with MAS and treated with pulses of methylprednisolone (30 mg/kg/dose) and IVIG, followed by high-dose oral prednisone (2 mg/kg/day). Fevers and hypotension resolved. She developed a large pericardial effusion that required drainage. Following this, she developed thrombocytopenia, with persistent platelet counts of 5 to 25 × 109/l. At this point complement levels were found to have normalized. Due to persistent thrombocytopenia, cyclosporine was begun at 2 mg/kg/day, which resulted in improvement of platelet counts. Several months later, after recurrence of pericarditis and fever, she was given anakinra. Since starting anakinra, she has been stable. Soluble CD25 level, near the end of disease course, was 11,670 pg/ml (normal < 2500 pg/ml), and natural killer function was decreased, at 0.3 lytic units.

Patient 3, a 17-year-old girl, presented with fever, arthralgia, wrist swelling, and rash. Initial laboratory findings were notable for elevated markers of inflammation (ESR 40 mm/h and CRP 16.44 mg/dl). She was initially managed with indomethacin, but over 2 weeks she developed quotidian fever and evanescent rash with Koebner phenomenon, and began to appear more ill. Laboratory evaluation at that time showed acute anemia (hemoglobin 8.0 g/dl) and thrombocytopenia (platelet count 95 × 109/l), and acute renal and liver dysfunction, with creatinine 1.7 mg/dl, alanine aminotransferase 153 IU/l, aspartate aminotransferase 208 IU/l. She developed hypotension, acute respiratory distress, and mild cardiac dysfunction. Initial and subsequent laboratory results are shown in Table 1. Complement levels, obtained due to observations of previous patients with hypocomplementemia and MAS, were markedly decreased. Ferritin was elevated. Bone marrow biopsy did not show hemophagocytosis, but rare hemophagocytosis was seen on a peripheral blood smear. An extensive infectious investigation was negative. ANA, ANCA, and all extractable nuclear antigens were negative. She was diagnosed with Still’s disease with progression to MAS and was treated with pulse methylprednisolone 30 mg/kg/dose for 3 days, followed by high-dose oral prednisone (30 mg BID), with improvement of clinical condition within days, decline in liver enzymes, and normalization of serum creatinine. She had normalization of complement levels and ferritin by 6 weeks after her critical illness. She was subsequently tapered slowly on steroids, and continues a low maintenance dose.

The diagnosis of MAS is often a challenge as it may mimic a flare of the underlying disease. Accurate and reasonably rapid discrimination of MAS from other mimicking conditions is important to avoid delay of treatment. Occult hemophagocytosis at high rates has been reported in patients with sJIA without other evidence of MAS6. Diagnostic guidelines specific for MAS complicating sJIA were proposed by Ravelli, et al in 20057. However, these criteria have not yet been validated. Marked hyperferritinemia (> 10,000 ng/ml) has also been found to be a strong indicator of MAS8.

Hypocomplementemia was not among the 13 laboratory criteria evaluated by Ravelli and colleagues, and it has not been noted as a feature of MAS complicating sJIA in our review of the literature. Further study may show this to be a useful laboratory discriminator in the critical phase of illness. Addition of hypocomplementemia as one of the discriminating features of MAS complicating sJIA may add to the overall sensitivity and specificity of diagnostic criteria.

The molecular mechanisms underlying hypocomplementemia may be related to the markedly increased production of a urokinase-like plasminogen activator by activated macrophages in MAS9. Plasminogen activator converts plasminogen to form plasmin, which is believed to activate the complement system10,11.

Further clinical cases may show hypocomplementemia to be a feature of MAS associated with sJIA, and to be useful as a discriminating laboratory feature for cases progressing to MAS.

REFERENCES

  1. 1.↵
    1. Ravelli A
    . Macrophage activation syndrome. Curr Opin Rheumatol 2002;14:548–52.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Kelly A,
    2. Ramanan AV
    . Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr Opin Rheumatol 2007;19:477–81.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Hadchouel M,
    2. Prieur AM,
    3. Griscelli C
    . Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drug or infection. J Pediatr 1985;106:561–6.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Koné-Paut I,
    2. Galambrun C,
    3. Mouy R,
    4. Bader-Meunier B,
    5. Prieur AM
    . Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology 2001;40:1285–92.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Pringe A,
    2. Trail L,
    3. Ruperto N,
    4. Buoncompagni A,
    5. Loy A,
    6. Breda L,
    7. et al.
    Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication? Lupus 2007;16:587–92.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Behrens EM,
    2. Beukelman T,
    3. Paessler M,
    4. Cron RQ
    . Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007;34:1133–8.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Ravelli A,
    2. Magni-Manzoni S,
    3. Pistorio A,
    4. Besana C,
    5. Foti T,
    6. Ruperto N,
    7. et al.
    Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005;146:598–604.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Fautrel B,
    2. Le Moël G,
    3. Saint-Marcoux B,
    4. Taupin P,
    5. Vignes S,
    6. Rozenberg S,
    7. et al.
    Diagnostic value of ferritin and glycosylated ferritin in adult onset Still’s disease. J Rheumatol 2001;28:322–9.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. de Saint Basile G,
    2. Fischer A,
    3. Dautzenberg MD,
    4. Durandy A,
    5. Le Deist F,
    6. Angles-Cano E,
    7. et al.
    Enhanced plasminogen-activator production by leukocytes in the human and murine Chediak-Higashi syndrome. Blood 1985;65:1275–81.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Schaiff WT,
    2. Eisenberg PR
    . Direct induction of complement activation by pharmacologic activation of plasminogen. Coron Artery Dis 1997;8:9–18.
    OpenUrlPubMed
  11. 11.↵
    1. Amara U,
    2. Rittirsch D,
    3. Flierl M,
    4. Bruckner U,
    5. Klos A,
    6. Gebhard F,
    7. et al.
    Interaction between the coagulation and complement system. Adv Exp Med Biol 2008;632:71–9.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 38, Issue 2
1 Feb 2011
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Hypocomplementemia Associated with Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still’s Disease: 3 Cases
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Hypocomplementemia Associated with Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still’s Disease: 3 Cases
MARK GORELIK, KATHRYN S. TOROK, DANIEL A. KIETZ, RAPHAEL HIRSCH
The Journal of Rheumatology Feb 2011, 38 (2) 396-397; DOI: 10.3899/jrheum.100833

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Hypocomplementemia Associated with Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still’s Disease: 3 Cases
MARK GORELIK, KATHRYN S. TOROK, DANIEL A. KIETZ, RAPHAEL HIRSCH
The Journal of Rheumatology Feb 2011, 38 (2) 396-397; DOI: 10.3899/jrheum.100833
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Does the BNT162b2 Vaccine Trigger Antimelanoma Differentiation-Associated Gene 5 Antibody–Positive Interstitial Lung Disease?
  • Duration of Steroid Therapy and Temporal Artery Biopsy Positivity in Giant Cell Arteritis: A Retrospective Cohort Study
  • Desk Rejections: Not Without Due Deliberation
Show more Letters

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire